Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Rheumatoid Arthritis
Both
Rheumatoid Arthritis
Trial Information
Epidemiology, Correlation and Predictive Value of Disease Activity and Biomarkers in RA Patients Initiated on Infliximab in Clinical Practice
Inclusion Criteria:
- Subject has been diagnosed with RA
- Physician has decided, with the subject's consent, to begin treatment with infliximab
- Written informed consent form signed by both the subject and the physician.
Exclusion Criteria:
- Subjects who have previously been exposed to infliximab
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Baseline Raw Disease Activity Score for 28 Joint Swollen and Tender Joint Count (DAS28) by Age
Outcome Description:
Results are reported as the mean DAS28 raw score at Baseline. DAS28 is a unit scale from 2.0 (best value) to 10.0 (worst value). The relationship between Baseline Raw DAS28 and Baseline age (see Baseline Characteristics) is reported in the statistical analysis.
Outcome Time Frame:
At Baseline
Safety Issue:
No
Authority:
United States: Institutional Review Board
Study ID:
P04250
NCT ID:
NCT00705289
Start Date:
December 2005
Completion Date:
September 2008
Related Keywords:
- Rheumatoid Arthritis
- Arthritis
- Arthritis, Rheumatoid
Name | Location |
|---|
